Docetaxel and Cetuximab in Patients With Docetaxel-resistant Hormone-refractory Prostate Cancer (HRPC). A Multicenter Phase II Trial.
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2013
At a glance
- Drugs Cetuximab (Primary) ; Docetaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 25 Jun 2012 Actual end date Apr 2010 added as reporetd by ClinicalTrials.gov.
- 25 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.